It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Disrupted homeostasis of the microtubule binding protein tau is a shared feature of a set of neurodegenerative disorders known as tauopathies. Acetylation of soluble tau is an early pathological event in neurodegeneration. In this work, we find that a large fraction of neuronal tau is degraded by chaperone-mediated autophagy (CMA) whereas, upon acetylation, tau is preferentially degraded by macroautophagy and endosomal microautophagy. Rerouting of acetylated tau to these other autophagic pathways originates, in part, from the inhibitory effect that acetylated tau exerts on CMA and results in its extracellular release. In fact, experimental blockage of CMA enhances cell-to-cell propagation of pathogenic tau in a mouse model of tauopathy. Furthermore, analysis of lysosomes isolated from brains of patients with tauopathies demonstrates similar molecular mechanisms leading to CMA dysfunction. This study reveals that CMA failure in tauopathy brains alters tau homeostasis and could contribute to aggravate disease progression.
The tau protein has been implicated in neurodegenerative disorders and can propagate from cell to cell. Here, the authors show that tau acetylation reduces its degradation by chaperone-mediated autophagy, causing re-routing to other autophagic pathways and increasing extracellular tau release.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Roche Chile Pharmaceuticals, Las Condes, Chile (GRID:grid.508828.f)
2 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Institut des Maladies Neurodégénératives, CNRS, Université de Bordeaux, Bordeaux, France (GRID:grid.462010.1)
3 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Universidad Autonoma de Madrid, Institute Teofilo Hernando for Drug Discovery, Department of Pharmacology, School of Medicine, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Instituto de Investigación Biosanitaria Hospital de la Princesa, Madrid, Spain (GRID:grid.411251.2) (ISNI:0000 0004 1767 647X)
4 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997)
5 Weill Cornell Medicine, Helen and Robert Appel Alzheimer’s Disease Research Institute, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
6 Harvard Medical School, Massachusetts General Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
7 University of California at San Francisco, Institute for Neurodegenerative Disease, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
8 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Instituto Ramón y Cajal de Investigaciones Sanitarias Hospital Ramón y Cajal, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770)
9 Universidad Autonoma de Madrid, Institute Teofilo Hernando for Drug Discovery, Department of Pharmacology, School of Medicine, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Instituto de Investigación Biosanitaria Hospital de la Princesa, Madrid, Spain (GRID:grid.411251.2) (ISNI:0000 0004 1767 647X)
10 Washington University, Department of Psychiatry, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
11 Icahn School of Medicine at Mount Sinai, Department of Neuroscience, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
12 Harvard Medical School, Massachusetts General Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)